Will IMMUDYNE INCORPORATED (OTCMKTS:IMMD) Run Out of Steam Soon? Short Interest Is Down

February 14, 2018 - By Darrin Black

The stock of IMMUDYNE INCORPORATED (OTCMKTS:IMMD) registered a decrease of 26.45% in short interest. IMMD’s total short interest was 58,400 shares in February as published by FINRA. Its down 26.45% from 79,400 shares, reported previously. With 107,100 shares average volume, it will take short sellers 1 days to cover their IMMD’s short positions.

The stock decreased 1.30% or $0.004 during the last trading session, reaching $0.285. About shares traded. ImmuDyne, Inc. (OTCMKTS:IMMD) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Immudyne, Inc. manufactures, distributes, and sells natural immune support products primarily in the United States. The company has market cap of $12.65 million. It operates in two divisions, Nutraceutical and Cosmetic Additives, and Finished Cosmetic Products. It currently has negative earnings. The firm offers nutraceutical and cosmetic product lines, including yeast beta glucans that are natural extracts for various oral and topical applications.

More notable recent ImmuDyne, Inc. (OTCMKTS:IMMD) news were published by: Globenewswire.com which released: “Immudyne Announces Definitive Endorsement Agreement with Leading Dermatologist” on December 07, 2016, also Globenewswire.com with their article: “ImmuDyne Announces New CFO to Take Company through Next Phase of Growth” published on October 04, 2017, Globenewswire.com published: “ImmuDyne Appoints Chief Operating Officer/Chief Technology Officer” on February 23, 2017. More interesting news about ImmuDyne, Inc. (OTCMKTS:IMMD) were released by: Globenewswire.com and their article: “ImmuDyne Announces Record Third Quarter 2017 Revenue” published on October 16, 2017 as well as Globenewswire.com‘s news article titled: “ImmuDyne, Inc. Announces Annual Filing Update” with publication date: April 17, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.